Systems Pharmacology Publications

The global relationship between therapeutic drugs and human genome is largely unexplored. Systems Pharmacology is focused on understanding drug action both therapeutic and adverse from a network perspective with the goal of anchoring all drug action in the human interactome. Such a holistic approach will be useful both for drug discovery, especially polypharmacology for complex diseases and prediction of adverse events. One long-term goal is to be able to develop algorithms that predict therapeutic efficacy and adverse event probability in individual patients. Members of SBCNY are actively working in the area of Systems Pharmacology and have made some of the earliest contributions to this emerging field.

Image: A network map of the FDA approved drugs and their protein targets in human cells. The image represents a bipartite network of interactions between drugs and their human gene products. The information about these interactions was obtained from the FDA Electronic Orange Book (EOB) and DrugBank. Gray nodes represent drugs and yellow nodes their known human protein targets (Entrez Gene names). [Source:Ma'ayan A, Jenkins SL, Goldfarb J, Iyengar R. Network analysis of FDA approved drugs and their targets. Mt Sinai J Med. 2007 Apr;74(1):27-32.]

Ma'ayan A, Jenkins SL, Goldfarb J, Iyengar R. Network analysis of FDA approved drugs and their targets. Mt Sinai J Med. 2007 Apr;74(1):27-32.
PMID: 17516560 | PMCID: PMC2561141 | EndNote Citation

Wist AD, Berger SI, Iyengar R. Systems pharmacology and genome medicine: a future perspective. Genome Med. 2009 Jan 22;1(1):11.
PMID: 19348698 | PMCID: PMC2651594 | EndNote Citation

Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009 Oct 1;25(19):2466-72.
PMID:19648136 | PMCID: PMC2752618 | EndNote Citation

Berger SI, Ma'ayan A, Iyengar R. Systems pharmacology of arrhythmias. Sci Signal. 2010 Apr 20;3(118):ra30.
PMID: 20407125 | PMCID: PMC3068558 | EndNote Citation

Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel. 2010 May;13(3):297-309.
PMID: 20443163 | PMCID: PMC3068535 | EndNote Citation

Boran AD, Iyengar R. Systems pharmacology. Mt Sinai J Med. 2010 Jul-Aug;77(4):333-44.
PMID: 20687178 | PMCID: PMC3113679 | EndNote Citation

Berger SI, Iyengar R. Role of systems pharmacology in understanding drug adverse events. Wiley Interdiscip Rev Syst Biol Med. 2010 Aug 27
PMID: 20803507 | PMCID: PMC3057924 | EndNote Citation

Zhao S, Iyengar R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol. 2012 Feb 10;52:505-21.
PMID: 22235860 | EndNote Citation

Hansen J, Zhao S, Iyengar R. Systems pharmacology of complex diseases. Ann N Y Acad Sci. 2011 Dec;1245:E1-5.
PMID: 22319785 | EndNote Citation

Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM. Merging systems biology with pharmacodynamics. Sci Transl Med. 2012 Mar 21;4(126):126ps7.
PMID: 22440734 | EndNote Citation

Jenkins SL, Ma'ayan A. Systems pharmacology meets predictive, preventive, personalized and participatory medicine Pharmacogenomics. 2013 Jan;14(2):119-22
PMID: 23327571 | EndNote Citation

Duan Q, Kou Y, Clark NR, Gordonov S, Ma'ayan A. Metasignatures Identify Two Major Subtypes of Breast Cancer. CPT: Pharmacometrics & Systems Pharmacology (2013)
Article | PMID: 23836026 | PMCID: PMC3615534 | EndNote Citation

Zhao S, Nishimura T, Chen Y, Azeloglu EU, Gottesman O, Giannarelli C, Zafar MU, Benard L, Badimon JJ, Hajjar RJ, Goldfarb J, Iyengar R.Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med. 2013 Oct 9;5(206):206ra140
PMID: 24107779 | Supplementary Materials | EndNote Citation

Last Updated: